YE Hanyang,JIN Lingwei,JIN Jian, et al. Expression and significance of CXCL-16 in chronic kidney disease[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2014, 44(12): 887-891.
Abstract：Objective: To study the effect of C-X-C chemokine ligand 16 (CXCL16) in patients with chronic kidney disease (CKD) and animal models of nephritic syndrome. To investigate whether elevated CXCL16 concentrations were associated with renal failure in the development of CKD. Methods: Serum samples of 40 healthy people and 200 CKD subjects including our patients and long-term hemodialytic patients were collected. Plasma CXCL16 levels and other clinical and biochemical parameters in all subjects were obtained based on the clinical examinational standard methods. As for experimental animals, 14 male C57BL/6 rats were obtained, which were distributed into common control group and common model group. 7 CXCL16 knockout rats which were randomly distributed into knockout control group and knockout model group were also obtained. Their living conditions were observed for 4 weeks. After that, they were killed and their serum urea nitrogen, creatine, CXCL16 and other indexes were determined; the pathological changes of their kidney tissues were observed. Results: Plasma CXCL16 levels were significantly increased with the development of CKD from early-and end-stage (P<0.001 for trend), median circulating CXCL16 level was higher in end-stage CKD patients compared with the early-stage CKD patients and the middle-stage CKD patients. After adjusting for age, gender, and body mass index (BMI), plasma CXCL-16 levels significantly associated with renal function and other factors in CKD subjects. Correlative analysis showed the level of CXCL16 was positively associated with serum urea nitrogen, serum creatine, CRP and adiponectin (P<0.05), and negatively associated with eGFR, HDL-C. In the animal experiments, compared with those in common model group, the increments of serum urea nitrogen, creatine and uric acid in knockout model group were much lower. Renal pathology indicated the level of kidney damage in knockout model group was lower than that in common model group. Conclusion: Plasma CXCL16 levels are significantly increased with the development of early-to end-stage CKD and are independently associated with the loss of renal function. Understanding whether increased CXCL16 is a marker or a potential mechanism of myocardial hypertrophy in CKD requires further study.
[1]Yokozawa T, Zheng PD, Oura H, et al. Animal model of ad-enine-induced chronic renal failure in rats[J]. Nephron, 1986, 44(3): 230-234.
[2]Norlander AE, Saleh MA, Modhur MS, et al. A chemokine-causing chronic kidney disease[J]. Hypertension, 2013, 62: 1008-1010.
[3]Gutwein P, Abdel-Bakky MS, Schramme A, et al. CXCL16 is expressed in podocytes and acts as a scavenger receptor for oxidized low-density lipoprotein[J]. Am J Pathol, 2009, 174(6): 2061-2072.
[4]Wu T, Xie C, Wang HW, et al. Elevated urinary VCAM-1,P-selectin, soluble TNF receptor-1, and CXC chemo-kine ligand 16 in multiple murine lupus strains and human lupus nephritis[J]. J Immunol, 2007, 179(10): 7166-7175.
[5]吴帆, 龚琦, 俞佳文, 等. 痛风患者CXCL16血清水平的变化及临床意义[J]. 中国病理生理杂志, 2011, 27(10): 1977-1981.
[6]Okamura DM, Lopez-Guisa JM, Koelsch K, et al. Athero-genic scavenger receptor modulation in the tubulointersti-tium in response to chronic renal injury[J]. Am J Physiol Renal Physiol, 2007, 293(2): F575-F585.
[7]Schramme A, Abdel-Bakky MS, Gutwein P, et al. Characterization of CXCL16 and ADAM10 in the normal and transplanted kidney[J]. Kidney Int, 2008, 74(3): 328-338.
[8]Xia Y, Entman ML, Wang Y, et al. Critical role of CXCL16 in hypertensive kidney injury and fibrosis[J]. Hypertension, 2013, 62(6): 1129-1137.
